Twice-Daily Proton Pump Inhibitor Induces Higher Remission Rate in Eosinophilic Esophagitis Than Once-Daily Regimen Regardless of Total Daily Dose

被引:4
|
作者
Muftah, Mayssan [1 ,2 ]
Goldin, Alison H. [1 ,2 ]
Barshop, Kenneth [2 ,3 ]
Blatman, Karen Hsu [2 ,4 ]
Hamilton, Matthew J. [1 ,2 ]
Lo, Wai-Kit [1 ,2 ]
Hornick, Jason L. [2 ,5 ]
Chan, Walter W. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol, Hepatol & Endoscopy, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[4] Brigham & Womens Hosp, Div Allergy & Clin Immunol, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 05期
关键词
eosinophilic esophagitis; proton pump inhibitor; drug dosing; eosinophil; esophageal biopsies; histologic response; MANAGEMENT;
D O I
10.14309/ajg.0000000000002712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: The optimal proton pump inhibitor (PPI) regimen for eosinophilic esophagitis (EoE) is unclear. We compared histologic response rates of different dosing combinations. METHODS: A total of 305 patients with newly diagnosed EoE received standard (omeprazole 20 mg daily), once-daily moderate (40 mg daily), twice-daily moderate (20 mg twice daily), or high (40 mg twice daily) dose PPI for >= 8 weeks. RESULTS: Approximately 42.3% achieved histologic response to PPI, with higher rates for twice-daily (moderate 52.8%/high 54.3%) than once-daily (standard 11.8%/moderate 10%) dosing (P < 0.0001). On multivariable analysis, twice-daily moderate (adjusted odds ratio 6.75, confidence interval 2.53-18.0, P = 0.0008) and high (adjusted odds ratio 12.8, confidence interval 4.69-34.8, P < 0.0001) doses independently predicted histologic response. DISCUSSION: Twice-daily PPI is associated with higher EoE histologic response rates than once-daily regimen.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [41] A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks
    Molina, Jean-Michel
    Podsadecki, Thomas J.
    Johnson, Margaret A.
    Wilkin, Aimee
    Domingo, Pere
    Myers, Robert
    Hairrell, Jan M.
    Rode, Richard A.
    King, Martin S.
    Hanna, George J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (12) : 1505 - 1514
  • [42] Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection
    Akshanth R. Polepally
    Haoyu Wang
    Patrick J. Marroum
    Mukul Minocha
    Balakrishna Hosmane
    Amit Khatri
    Sven Mensing
    Thomas J. Podsadecki
    Daniel E. Cohen
    Walid M. Awni
    Rajeev M. Menon
    The AAPS Journal, 2017, 19 : 1523 - 1535
  • [43] Once-daily MMX® 5-aminosalicylic acid versus twice-daily Asacol® for the maintenance of remission of ulcerative colitis:: a preliminary analysis
    Prantera, Cosimo
    Kohn, Anna
    Campieri, M.
    Caprilli, Renzo
    Sturniolo, Giacomo C.
    Vecchi, Maurizio
    Pallone, F.
    Cottone, Mario
    Bellinvia, Salvatore
    GASTROENTEROLOGY, 2008, 134 (04) : A491 - A491
  • [44] A MULTIPLE-DOSE PHARMACOKINETIC COMPARISON OF NAPROXEN AS A ONCE-DAILY CONTROLLED-RELEASE TABLET AND A TWICE-DAILY CONVENTIONAL TABLET
    LING, TL
    YEE, JP
    COHEN, A
    HSIAO, C
    GONZALEZ, MA
    GARG, DC
    WEIDLER, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (04): : 325 - 329
  • [45] A DOUBLE-BLIND-STUDY OF ONCE-DAILY VERSUS TWICE-DAILY DOSE OF PENBUTOLOL ON THE TOLERANCE IN STABLE ANGINA-PECTORIS
    HOUTZAGERS, JJR
    CHADHA, DR
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1980, 28 (04): : 515 - 519
  • [46] TWICE DAILY PPI IS ASSOCIATED WITH BETTER DELINEATION OF PPI-REE DIAGNOSIS THAN ONCE DAILY PPI TRIAL REGARDLESS OF TOTAL DAILY DOSAGE
    Goldin, Alison
    Barshop, Kenneth
    Blatman, Karen S. Hsu
    Hamilton, Matthew
    Lo, Wai-Kit
    Hornick, Jason
    Chan, Walter W.
    GASTROENTEROLOGY, 2017, 152 (05) : S874 - S875
  • [47] Conversion of stable liver transplant recipients from a twice-daily prograf-based regimen to a once-daily modified release tacrolimus-based regimen
    Florman, S
    Alloway, R
    Kalayoglu, M
    Lake, K
    Bak, T
    Klein, A
    Klintmalm, G
    Busque, S
    Brandenhagen, D
    Lake, J
    Wisemandle, K
    Fitzsimmons, W
    First, MR
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 1211 - 1213
  • [48] What Is the Best Strategy for Converting from Twice-Daily Divalproex to a Once-Daily Divalproex ER Regimen?Examinations and Answers via Computer Simulations
    Ronald C. Reed
    Sandeep Dutta
    Clinical Drug Investigation, 2004, 24 : 509 - 521
  • [49] What is the best strategy for converting from twice-daily Divalproex to a once-daily Divalproex ER regimen? Examinations and answers via computer simulations
    Reed, RC
    Dutta, S
    CLINICAL DRUG INVESTIGATION, 2004, 24 (09) : 509 - 521
  • [50] LOFEXIDINE IN THE TREATMENT OF HYPERTENSION - A TWICE-DAILY VERSUS ONCE-DAILY DOSE COMPARISON WITH 24-HOUR BLOOD-PRESSURE MONITORING
    GARRETT, BN
    KAPLAN, NM
    JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (04): : 173 - 180